Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760249 | 1.00 | MAPT (0.47) | MAPTCYP2C19MEN1KMT2ACYP3A4 | |
| SCHEMBL1760250 | 1.00 | MAPT (0.47) | MAPTCYP2C19MEN1KMT2ACYP3A4 | |
| SCHEMBL24658442 | 0.81 | APP (0.37) | APP | |
| SCHEMBL7302041 | 0.80 | HTR2A (0.46) | GRIK1GRIK2 | |
| SCHEMBL7302039 | 0.80 | HTR2A (0.46) | GRIK1GRIK2 | |
| SCHEMBL1759802 | 0.74 | APP (0.51) | MAPTMEN1KMT2AGRIK1GRIK2 | |
| SCHEMBL1772978 | 0.74 | APP (0.51) | MAPTMEN1KMT2AGRIK1GRIK2 | |
| SCHEMBL1772975 | 0.74 | APP (0.51) | MAPTMEN1KMT2AGRIK1GRIK2 | |
| SCHEMBL8783725 | 0.74 | MAPT (0.52) | MAPTCYP2C19MEN1KMT2ACYP3A4 | |
| SCHEMBL8783722 | 0.74 | MAPT (0.52) | MAPTCYP2C19MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2635560-B1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-8673950-B2 | Dihydrooxazol-2-amine derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673950-B2 | Dihydrooxazol-2-amine derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130345241-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2635560-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012059371-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20120108609-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-03 | — | — | US | disclosed |
| US-20120108609-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-03 | — | — | US | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108609-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | TAAR1, TAAR5, HCRTR1 | MAPT 205/4885CYP2C19 382/4885MEN1 1676/4885 |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | MAPT 231/4885CYP2C19 356/4885MEN1 1598/4885 |
| US-20130345241-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | TAAR1, TAAR5, HCRTR1 | MAPT 204/4885CYP2C19 363/4885MEN1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.